[Perspectives and challenges of malaria vaccine. Why we must do more].
During the last 10 years the development of a malaria vaccine has attracted an increasing amount of attention both from the political sector and from financial investors. This has led to a number of major scientific and technological advances, but much remains to be done. Numerous potential target antigens are under investigation, and most research is focusing on a subunit vaccine. Irradiated attenuated sporozoites are also a promising approach, even if major technological and regulatory challenges remain to be overcome. Barriers to vaccine development include an inadequate understanding of certain aspects of host-parasite biology and protective immune responses. Other challenges are to increase the antigenicity of some antigens, and to optimize the quality of the immune response. However, research funding remains the main obstacle.
Leroy
Odile
O
European Malaria Vaccine Initiative, Artillerivej 5, Copenhague 2300S Danemark. oly@ssi.dk
D000818:Animals; D000852:Anopheles / Q000469:parasitology; D005544:Forecasting; D006801:Humans; D007303:Insect Vectors / Q000469:parasitology; D008018:Life Cycle Stages; D008288:Malaria / Q000517:prevention & control; D017780:Malaria Vaccines / Q000276:immunology; D016778:Malaria, Falciparum / Q000517:prevention & control; D010963:Plasmodium falciparum / Q000276:immunology / Q000502:physiology / Q000528:radiation effects; D014613:Vaccines, Attenuated; D022223:Vaccines, Subunit / Q000276:immunology
D017780:Malaria Vaccines; D014613:Vaccines, Attenuated; D022223:Vaccines, Subunit